Advertisement

Topics

Magenta Therapeutics, Inc. Company Profile

07:03 EDT 18th July 2018 | BioPortfolio


News Articles [793 Associated News Articles listed on BioPortfolio]

Pfizer’s John Davis Named Magenta Therapeutics Chief Medical Officer

Magenta Therapeutics has recruited Pfizer (NYSE: PFE) executive John Davis to serve as the startup’s new chief medical officer. Before coming to Cambridge, MA-based Magenta, Davis was Pfizer’s sen...

Magenta Therapeutics Snags $52 Million to Advance Bone Marrow Transplant Medications

Fresh off of striking a research deal with Ladenburg, Germany-based Heidelberg Pharma GmbH, Magenta Therapeutics secured $52 million.The funds will be used to advance Magenta's portfolio of bone marro...

Heidelberg Pharma und Magenta Therapeutics unterzeichnen exklusive Forschungsvereinbarung

Bad Marienberg - Die Heidelberg Pharma AG (ISIN DE000A11QVV0/ WKN A11QVV), ein biotechnologisches Unternehmen, das neue Möglichkeiten in der Krebstherapie erforscht, und Magenta Therapeutics Inc., .....

Magenta Therapeutics and Heidelberg Pharma partner in ADC collaboration

Magenta Therapeutics Inc. and Heidelberg Pharma AG teamed up to discover and develop antibodies that improve bone marrow transplantation procedures for cancer patients.

Magenta’s Bastiano Sanna Appointed Semma Therapeutics CEO

Bastiano Sanna has been named CEO and president of Semma Therapeutics. Elizabeth Stoner, who has been serving as interim CEO, will remain as an advisor to the company. Sanna comes to Cambridge, MA-bas...

Heidelberg Pharma: Lizenz- und Forschungsdeal mit Magenta Therapeutics

Heidelberg Pharma hat mit Magenta Therapeutics eine Kooperation im Bereich der Wirkstoffforschung vereinbart. "Heidelberg Pharma Research GmbH unterzeichnete die Vereinbarung, bei der aus Magentas ...

Magenta Therapeutics and Heidelberg Pharma sign exclusive deal

USA and Germany-based biotech firms Magenta Therapeutics and Heidelberg Pharma have signed an exclusive…

Initial public offering nets $93mm for Magenta Therapeutics

Magenta Therapeutics Inc. (curative stem cell transplantation) netted $93mm through its initial public offering of 6.67mm common shares at $15, the midpoint of its anticipated range.

PubMed Articles [446 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Introduction to Volume 2 of JOPT Special Issue.

Clinical Trials [148 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1244 Associated Companies listed on BioPortfolio]

Magenta Therapeutics Inc.

Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic di...

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based dise...

Magenta Therapeutics, Inc.

Magenta Medical Inc.

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Magenta Therapeutics, Inc." on BioPortfolio

We have published hundreds of Magenta Therapeutics, Inc. news stories on BioPortfolio along with dozens of Magenta Therapeutics, Inc. Clinical Trials and PubMed Articles about Magenta Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Magenta Therapeutics, Inc. Companies in our database. You can also find out about relevant Magenta Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record